ArticleeLife2014
Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4(+) T cells tolerized by peptide immunotherapy.
Article in eLife, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 56 citations in OpenAlex.
- Trial
- Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.Cellular immunology · 2017Trial
- Review
- 5-Hydroxymethylcytosine in Cell-Free DNA Predicts Immunotherapy Response in Lung Cancer.Cells · 2024Article
- Deciphering Glioblastoma: Fundamental and Novel Insights into the Biology and Therapeutic Strategies of Gliomas.Current issues in molecular biology · 2024Review
- CBX4 promotes antitumor immunity by suppressing Pdcd1 expression in T cells.Molecular oncology · 2023Article
- PD-1/PD-L1 axis in organ fibrosis.Frontiers in immunology · 2023Review
- Epigenome-Driven Strategies for Personalized Cancer Immunotherapy.Cancer management and research · 2023Review
- IL-6/STAT3 Signaling Axis Enhances and Prolongs Pdcd1 Expression in Murine CD8 T Cells.ImmunoHorizons · 2022Article
- Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma.International journal of molecular sciences · 2022Review
- Diverse antitumor effects of ascorbic acid on cancer cells and the tumor microenvironment.Frontiers in oncology · 2022Review
- Transcriptional and epigenetic regulation of PD-1 expression.Cellular and molecular life sciences : CMLS · 2021Review
- KLHL22 maintains PD-1 homeostasis and prevents excessive T cell suppression.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response.Journal of clinical medicine · 2020Review
- PD-1 Expression during Acute Infection Is Repressed through an LSD1-Blimp-1 Axis.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- IFN-γ: A cytokine at the right time, is in the right place.Seminars in immunology · 2019Review
- PD-1 expression is upregulated on adapted T cells in experimental autoimmune encephalomyelitis but is not required to maintain a hyporesponsive state.European journal of immunology · 2019Article
- Vitamin C and immune cell function in inflammation and cancer.Biochemical Society transactions · 2018Review
- T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- The diverse functions of the PD1 inhibitory pathway.Nature reviews. Immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
Clinically effective antigen-based immunotherapy must silence antigen-experienced effector T cells (Teff) driving ongoing immune pathology. Using CD4(+) autoimmune Teff cells, we demonstrate that peptide immunotherapy (PIT) is strictly dependent upon sustained T cell expression of the co-inhibitory molecule PD-1. We found high levels of 5-hydroxymethylcytosine (5hmC) at the PD-1 (Pdcd1) promoter of non-tolerant T cells. 5hmC was lost in response to PIT, with DNA hypomethylation of the promoter. We identified dynamic changes in expression of the genes encoding the Ten-Eleven-Translocation (TET) proteins that are associated with the oxidative conversion 5-methylcytosine and 5hmC, during cytosine demethylation. We describe a model whereby promoter demethylation requires the co-incident expression of permissive histone modifications at the Pdcd1 promoter together with TET availability. This combination was only seen in tolerant Teff cells following PIT, but not in Teff that transiently express PD-1. Epigenetic changes at the Pdcd1 locus therefore determine the tolerizing potential of TCR-ligation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.